

ESMO Preceptorship Programme

Gastric Cancer

Multidisciplinary management, standards of care, therapeutic targets and future perspectives

4-5 September 2015, Brussels, Belgium

Chair: Eric Van Cutsem, Belgium

Co-Chair: Andrés Cervantes, Spain

Faculty:

Florian Lordick, Germany,

Pathology: Fatima Carneiro, Portugal

Radiation Oncology: Karin Haustermans, Belgium

Surgery: William Allum, UK

LEARNING OBJECTIVES

- To learn about the fundamentals of epidemiology, etiology, pathogenesis, molecular events and ethnic patterns as contributing factors to heterogeneity in gastric cancer
- To understand the essentials in the diagnosis and multidisciplinary treatment of gastric cancer
- To learn about advances in the treatment and novel targets in gastric cancer

Friday, 4 September 2015

09:00	Opening and Welcome	
5'	Welcome from ESMO	Eric Van Cutsem & Andrés Cervantes
5'	Objectives of the meeting	Eric Van Cutsem
09:15-11:00 105'	Module 1 Epidemiology, pathology and endoscopy of gastric cancer	
30'	Epidemiology (including GE junction tumors) and clinical presentation	Andrés Cervantes
30'	Pathology and carcinogenesis	Fatima Carneiro
30'	Endoscopy in gastric cancer: new imaging techniques, new treatment modalities (EMR, ESD)	TBC
15'	discussion	
11:00-11:30	Break	

11:30-13:00 90'	Module 2 Surgical, adjuvant and neoadjuvant treatment of gastric cancer	
30'	Surgery for gastric and GE junction cancer, primary, palliative - where and when?	William Allum
25'	Neo- and adjuvant treatment for gastric cancer and GE junction cancer: The role of radiotherapy	Karin Haustermans
25'	Neo- and adjuvant treatment for gastric cancer: The role of chemotherapy	Florian Lordick
10'	Discussion	

13:00-14:00	Lunch	
-------------	-------	--

14:00-15:00 50'	Module 3 Molecular biology in gastric cancer	
10	Molecular events and classification in gastric cancer	Fatima Carneiro
	discussion	

15:00 – 15:30	Break	
---------------	-------	--

15:30-17:30 120'	Module 4 Advanced disease	
30'	Chemotherapy for metastatic disease	Florian Lordick
40'	Biological targeted agents (including HER2, EGFR, angiogenesis,)	Eric Van Cutsem
40'	New targets (including cMET, FGF, mTOR, PDL...)	TBC
10'	Discussion	

19:00-22:00	Dinner	
-------------	--------	--

Saturday, 5 September 2015

08:45-10:30 105'	Module 5 Clinical discussions	
30'	Is the treatment of oesophageal adenocarcinoma similar to gastric adenocarcinoma?	TBC
5'	discussion	
70	Case presentations from the audience	Eric Van Cutsem & Andrés Cervantes & Florian Lordick & William Allum

10:30 – 11:00	Coffee break	
---------------	--------------	--

11:00-12:00 60'	Module 6 Practical case discussions	
60'	Case discussions based on ESMO recommendations/guidelines	Andrés Cervantes and Eric Van Cutsem

12:00-12:30 30'	Module 7 Future outlook	
20'	What we have learned from recent clinical studies and where do we go from here? Future outlook	Andrés Cervantes
10'	Closing remarks and take-home messages	Eric Van Cutsem & Andrés Cervantes